Related Experiment Video
Updated: May 9, 2026

07:02
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)
Published on: September 14, 2010
Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: experience with 10 patients
Casper Rokx1, Marchina E van der Ende, Annelies Verbon
1Department of Internal Medicine, Section on Infectiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Abstract:
In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.

